|
PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial). |
|
|
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche |
|
|
Honoraria - AMGEN; Bayer; Bristol-Myers Squibb; PRMA Consulting; Roche/Genentech; Sanofi; SERVIER; Xbiotech |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Guardant Health; HalioDX; MSD Oncology; Mundipharma; Roche/Genentech; SERVIER |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Amgen; Bayer Health; Sanofi |
Research Funding - Sanofi |
Travel, Accommodations, Expenses - Amgen; Bayer Health; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Roche |
Speakers' Bureau - Pierre Fabre; SERVIER |
Travel, Accommodations, Expenses - Lilly; Merck Serono; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Merck Serono |
Travel, Accommodations, Expenses - Amgen; Bayer; BioCodex; Ipsen; Merck Serono; Novartis; Roche |
|
|
Honoraria - Amgen; Celgene; Ipsen; Leo Pharma; Novartis |
Consulting or Advisory Role - Amgen; Celgene; LEO Pharma; Novartis; Pfizer; Shire; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Amgen; Ipsen; LEO Pharma; Novartis; Pfizer; Roche/Genentech |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Shire; Taiho Pharmaceutical |
Research Funding - Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; HalioDx; MSD Oncology; Pierre Fabre |
|
|
Consulting or Advisory Role - Amgen; Baxalta; Celgene; Lilly; Merck KGaA; Roche; SERVIER; Sirtex Medical |
Speakers' Bureau - Amgen; Baxalta; Lilly; Merck; Roche/Genentech; Sanofi; SERVIER |